Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Legend Biotech Corporation
Legend Biotech to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
May 23, 2024
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
May 13, 2024
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
April 22, 2024
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
April 11, 2024
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
April 05, 2024
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
March 19, 2024
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
March 15, 2024
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
March 11, 2024
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
February 23, 2024
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
February 13, 2024
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
January 03, 2024
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
December 11, 2023
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
November 20, 2023
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
November 13, 2023
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech to Host Investor Conference Call on Third-Quarter Results
November 07, 2023
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
November 02, 2023
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
August 15, 2023
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
August 03, 2023
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
June 06, 2023
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
May 25, 2023
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights
May 18, 2023
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings
May 16, 2023
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Participation in Upcoming Investor Conference
May 11, 2023
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares
May 08, 2023
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022
November 03, 2022
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
September 27, 2022
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022
August 05, 2022
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Legend Biotech Corporation Announces Pricing of Public Offering
July 26, 2022
From
Legend Biotech Corporation
Via
Business Wire
Tickers
LEGN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.